Other languages Cue Biopharma, Inc.

Equities

CUE

US22978P1066

Real-time Estimate Cboe BZX Other stock markets 17:34:08 02/05/2024 BST			5-day change	1st Jan Change
1.805 ^USD	-5.25%		+27.66%	-31.82%

04-08	Transcript : Cue Biopharma, Inc., Q4 2023 Earnings Call, Apr 08, 2024
04-08	North American Morning Briefing : Inflation Data, -2-	DJ

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Cue Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-28
Cue Biopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-03
Cue Biopharma Reports Prolonged Survival in Phase 1 Trials of CUE-101; Shares Climb	11-03
Cue Biopharma Presents New Positive Data from Phase 1 Trials of CUE-101 in Head and Neck Cancer and Cue-102 in Wilms' Tumor 1 Positive Cancers at SITC 2023	11-03
Cue Biopharma Announces Completion of Patient Enrollment in Phase 1b Study of CUE-101 in Combination with KEYTRUDA®?	26/09/23
Cue Biopharma, Inc. Announces Resignation of Aaron Fletcher as Member of the Board of Directors, Effective October 9, 2023	14/09/23
Cue Biopharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	08/08/23
Cue Biopharma Says Phase 1b Trial of CUE-101 With Pembrolizumab Shows 40% Overall Response Rate	26/05/23
Cue Biopharma, Inc. Presents Positive Data Update from Ongoing Phase 1 Trials of Cue-101 for Recurrent/Metastatichpv+ Head and Neck Squamous Cell Carcinoma At the 2023 American Society of Clinical Oncology Annual Meeting	25/05/23
Cue Biopharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	09/05/23
Cue Biopharma, Inc Appoints Pamela D. Garzone to Its Board of Directors	25/04/23
Cue Biopharma, Inc. Announces Appointment of Patrick Verheyen to Its Board of Directors	12/04/23
Ms. Howson Intends to Retire from the Board of Directors of Cue Biopharma, Inc	10/03/23
Cue Biopharma Signs Strategic Collaboration, Option Deal With Ono Pharmaceutical for CUE-401; Shares Decline	22/02/23
Cue Biopharma, Inc. Enters into A Strategic Collaboration and Option Agreement with Ono Pharmaceutical for Cue-401	22/02/23
Cue Biopharma, Inc. Announces the Appointment of Rafi Ahmed to its Scientific Advisory Board	16/02/23
Cue Biopharma, Inc. Announces Executive Changes	23/01/23
Cue Biopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	14/11/22
Cue Biopharma, Inc. Presents New Positive Data from Ongoing Phase 1 Trial of Cue-101 in Combination with Keytruda for Recurrent/Metastatic Hpv+ Head and Neck Cancer At the Society for Immunotherapy of Cancer’s 37th Annual Meeting	10/11/22
Cue Biopharma Head, Neck Cancer Treatment Candidate Granted FDA Fast Track Designation; Shares Rise	04/10/22

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Cue Biopharma, Inc.

Equities

CUE

US22978P1066

Other languages

Filters